Converging AI and antibody data to create a new paradigm for antibody-based drug discovery

PharmAbcine Inc., a next-generation antibody therapeutics company, announced on February 10 that it has entered into a partnership agreement with Arontier Inc., an AI-driven drug discovery company, to jointly develop an AI-based antibody innovation drug development platform.

PharmAbcine CEO Peter Sim stated, “By collaborating with Arontier, which possesses a strong foundation in AI-driven drug discovery, we will establish an advanced platform that accelerates the development of innovative antibody-based drugs. This partnership will not only create new business models for both companies but also enable PharmAbcine to leverage the platform to build a highly competitive AI-driven innovative drug pipeline in terms of both time and cost.”

Arontier CEO Junsu Ko commented, “With access to PharmAbcine’s extensive 20-year dataset of various antibodies and bioinformatics expertise, we will integrate AI into the selection of antibody-based therapeutics, allowing for a safer and more efficient development process. This collaboration will differentiate our business model and enhance the success rate of antibody-based drugs in clinical trials while significantly reducing both development time and investment costs.”

* For more information, please visit the link below

https://www.thebionews.net/news/articleView.html?idxno=12654

* Source : THE BIO (https://www.thebionews.net)